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We have previously shown that the putative mammalian retromer
components sorting nexins 1 and 2 (Snx1 and Snx2) result in
embryonic lethality when simultaneously targeted for deletion in
mice, whereas others have shown that H58 (also known as
mVps26), another retromer component, results in similar lethality
when targeted for deletion. In the current study, we address the
genetic interaction of these mammalian retromer components in
mice. Our findings reveal a functional interaction between H58,
SNX1, and SNX2 and strongly suggest that SNX2 plays a more
critical role than SNX1 in retromer activity during embryonic
development. This genetic evidence supports the existence of
mammalian retromer complexes containing SNX1 and SNX2 and
identifies SNX2 as an important mediator of retromer biology.
Moreover, we find that mammalian retromer complexes contain-
ing SNX1 and SNX2 have an essential role in embryonic develop-
ment that is independent of cation-independent mannose 6-phos-
phate receptor trafficking.
embryonic lethality  H58  vacuolar protein sorting  cation-independent
mannose 6-phosphate receptor  yolk sac
A membrane coat retromer complex mediates endosome-to-Golgi trafficking of the vacuolar hydrolase receptor Vps10p
in yeast (1). Retromer complexes are comprised of Vps35p,
Vps29p, Vps26p, Vps5p, and Vps17p. Mammalian orthologs for
each of these proteins, except Vps17p, have been identified,
thereby suggesting that mammalian cells may use a trafficking
complex similar in molecular composition to the yeast retromer
complex. Furthermore, recent studies employing cell lines indi-
cate that mammalian retromer complexes participate in traffick-
ing of the cation-independent mannose 6-phosphate receptor
(CI-MPR), the functional homolog of Vps10p, suggesting that
the function of retromer complexes may also be conserved
between yeast and mammals (2–4).
Sorting nexin (SNX) 1 and SNX2 are 63% identical at the
amino acid level and are both mammalian orthologs of Vps5p
(5). Despite their homology to Vps5p, the function of SNX1 and
SNX2 in mammalian cells is poorly understood. Originally
discovered in a screen designed to identify molecules involved in
lysosomal sorting of the epidermal growth-factor receptor (6),
SNX1 has also been shown to associate with a number of
different receptors as well as other putative mammalian retro-
mer components, including SNX2, in cultured cell lines (5, 7, 8).
However, the functional implications of these interactions re-
main obscure, and it has been difficult to differentiate between
potential roles for SNX1 and SNX2 in retromer complexes
versus roles for these sorting nexins separable from retromer
activity. In the present study, we sought to define the participa-
tion and activity of SNX1 and SNX2 in mammalian retromer
complexes through genetic analyses in mice. We provide genetic
evidence for the involvement of these sorting nexins in mam-
malian retromer complexes and reveal an essential role for SNX2
in retromer activity during embryonic development.
Methods
Animals. Generation of Snx1-deficient (Snx1tm1Mag) and Snx2-
deficient (Snx2tm1Mag) mice was described in ref. 9. H58-
deficient (Vps26tm1Cos) mice were a gift from Frank Costantini
(Columbia University, New York) and were identical in pheno-
type to those generated by a previously described gene trap,
which was presumed to disrupt H58 (10, 11). All mice were
maintained on a mixed genetic background. For embryonic
analysis, noon on the day of plug detection was counted as
embryonic day 0.5 (E0.5).
Genotyping. The Snx1 and Snx2 wild-type and targeted alleles
were detected as described in ref. 9, except that PCRs for the
different alleles were run separately. Genotyping primers and
PCR conditions for H58 amplification are described in Sup-
porting Methods, which is published as supporting information on
the PNAS web site.
Reverse Transcription (RT)-PCR. Total RNA was generated from a
litter of E8.5 wild-type CD-1 embryos or their yolk sacs by using
TRIzol reagent (Invitrogen) and were reverse transcribed, as
described in Supporting Methods. One microliter of each RT
reaction was amplified in a 50-l PCR by using primers described
in Supporting Methods. RT-PCRs were performed under iden-
tical conditions for 25 cycles and with a 55°C annealing temper-
ature. PCR products were analyzed with MULTIANALYST soft-
ware (Bio-Rad). EST IMAGE clones nos. 578066 (Snx1) and
891452 (Snx2) were used as cDNA templates to compare the
PCR amplification ability of the Snx1 and Snx2 primers used in
the RT-PCRs.
Cell Lines and Assays. Primary mouse embryonic fibroblasts
(MEFs) were isolated as described in ref. 9, except that H58/
embryos were dissected at E8.5. We established permanent,
monomorphic, contact-inhibited MEF cell lines by subculturing
cells continuously until they emerged from a crisis period of slow
growth (25 passages) as described in ref. 12 and 13. Immuno-
fluorescence analysis was performed as described in ref. 9 by
using polyclonal (anti-rat) anti-CI-MPR antibodies provided by
Nancy Dahms (Medical College of Wisconsin, Milwaukee, WI)
and by J. Paul Luzio (University of Cambridge, Cambridge,
U.K.), a monoclonal anti-EEA1 antibody (BD Biosciences), and
AlexaFluor-conjugated secondary antibodies (Molecular
Probes). Images were collected by using an Olympus DSU
spinning disk confocal microscope configured with an IX71
fluorescent microscope fitted with a PlanApo 60 oil objective
and Hamamatsu ORCA-ER digital camera. Fluorescent images
of X-Y sections at 0.15 m were collected sequentially by using
Intelligent Imaging Innovations SLIDEBOOK 4.1 software. The
final composite images were created by using PHOTOSHOP
(Adobe Systems, San Jose, CA). Western blots for CI-MPR
detection were performed on lysates prepared from untreated
cells or cells treated for 17 h with 40 gml cycloheximide
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(Sigma). Western blots for mVPS35 detection were performed
by using a polyclonal (anti-human) anti-Vps35 antibody (5)
provided by Carol Haft (National Institute of Diabetes and
Digestive and Kidney Diseases, Bethesda). Membranes were
probed with an anti-actin antibody (Santa Cruz Biotechnology)
to control for equal loading of lysates. Immunoblots were
developed with ECL-plus (Amersham Pharmacia), imaged by
autoradiography, and quantified by using a Fluor-S Imager
(Bio-Rad).
Yolk Sac and Visceral Endoderm Immunostaining. For analysis of
CI-MPR localization in yolk sac cells, embryos and extraembry-
onic yolk sacs were dissected at E8.5, and yolk sacs were
processed for whole-mount immunostaining. Isolation and prep-
aration of visceral endoderm cells for analysis of CI-MPR
localization is described in Supporting Methods. Yolk sacs and
visceral endoderm cells were processed for immunofluorescence
microscopy, as described in ref. 9 by using an anti-CI-MPR
antibody from P. Luzio, and mounted in Vectashield mounting
medium with DAPI (Vector Laboratories). Images were ac-
quired by using a Leica DML fluorescence microscope and SPOT
RT software (Diagnostic Instruments).
Results and Discussion
Genetic Interactions of Mammalian Retromer Components. Mice
doubly deficient for Snx1 and Snx2 were previously shown to die
at midgestation with developmental delay, although the single
mutants are fully viable (9). Mice deficient for the ortholog of
Vps26p, H58, die with a similar phenotype to Snx1/;Snx2/
embryos (10, 11). To determine whether these genes are epistatic
and provide genetic evidence for the existence of a mammalian
retromer complex containing SNX1 and SNX2, we crossed Snx1,
Snx2, and H58 mutant mice together.
The viability of Snx1/ and Snx2/ mice indicates that the
putative mammalian retromer complex does not require both
SNX1 and SNX2 to function during development. Likewise,
mice heterozygous for H58 develop without any overt
abnormalities. However, we recovered only 10% of expected
Snx2/;H58/ mice from Snx2/;H58/  Snx2/ or
Snx2/;H58/  Snx2/ matings, indicating that 90%
of Snx2/;H58/ embryos die during development (Table 1).
This result demonstrates a strong genetic interaction between
Snx2 and H58 and suggests that SNX2 plays a critical role in
retromer function during development. Conversely, no lethality
was associated with Snx1/;H58/ mice or embryos gener-
ated from Snx1/;H58/  Snx1/ or Snx1/;H58/ 
Snx1/ matings (Table 1), indicating that SNX1 has a weaker
interaction with H58 and the retromer complex compared with
SNX2.
Although Snx1/;Snx2/ mice are viable, 40% of
Snx1/;Snx2/ embryos were previously reported to die
during development, indicating that SNX1 and SNX2 are
not completely functionally redundant (9). Strikingly, we
found that no Snx1/;Snx2/;H58/ mice generated from
Snx2/;H58/  Snx1/;Snx2/ matings survived develop-
ment (Table 2). On the other hand, Snx1/;Snx2/;H58/ mice
generated from Snx1/;H58/  Snx1/;Snx2/ matings were
viable (Table 2). Therefore, whereas SNX1 does not seem to have
as critical a role in retromer activity as does SNX2, SNX1 appears
to be present in retromer complexes during development as evi-
denced by its genetic interaction with Snx2 and H58. These data
provide genetic evidence that SNX1 and SNX2 have an important
role in mammalian retromer activity.
Embryonic Phenotypes. To determine the timing of Snx2/;H58/
and Snx1/;Snx2/;H58/ embryonic lethality and to compare
the phenotypes of those embryos to the previously described
phenotypes of H58/ and Snx1/;Snx2/ embryos (9–11), we
performed embryonic dissections (Fig. 4, which is published as
supporting information on the PNAS web site). Live Snx2/;
H58/ embryos were recovered as late as E18.5 with hemorrhage
and occasional exencephaly. The hemorrhagic events were evident
at different sites in the embryos; blood was occasionally observed
in the head with accompanying exencephaly or craniofacial abnor-
malities, whereas other embryos displayed prominent blood in the
abdomen rather than the head. Those Snx2/; H58/ embryos
unaffected by hemorrhage and exencephaly (10%) did not display
any overtly abnormal phenotypes and were viable and fertile after
birth.
Alternatively, both Snx1/;Snx2/;H58/ and 40% of
Snx1/;Snx2/ embryos died in two waves during develop-
ment. Both classes of embryos displayed an early wave of
lethality (E8.5) that was phenotypically similar to the lethality
observed in association with Snx1/;Snx2/ and H58/
embryos (9–11). These embryos were morphologically under-
developed and appeared to undergo developmental delay be-
ginning at E7.5. The second class of lethality observed with
Snx1/;Snx2/;H58/ and 40% of Snx1/;Snx2/ embryos
occurred E13.5 and was associated with exencephaly. This












Shown are the number of genotypes of live progeny from 28 litters gen-
erated by Snx2;H58  Snx2 or by Snx2;H58  Snx2
matings and 11 litters generated by Snx1;H58  Snx1 or by Snx1;
H58  Snx1 crosses. Note the 90% lethality for Snx2;H58
animals (P  0.001 by 2 test). *, the number of genotypes of live progeny from
11 litters generated by Snx1/;H58/  Snx1/ or by Snx1/;H58/ 
Snx1/ matings. No significant lethality was detected for Snx1;H58
animals.















Shown are the number of genotypes of live progeny from 24 litters
generated by Snx2;H58  Snx1;Snx2 matings and 11 litters
generated by Snx1;H58  Snx1;Snx2 matings. Note the com-
plete lethality for Snx1;Snx2;H58 animals (P  0.005 by 2 test). The
expected numbers account for 40% lethality of Snx1;Snx2 embryos, as
reported in ref. 9. *, the number of genotypes of live progeny from 11 litters
generated by Snx1/;H58/  Snx1/;Snx2/ matings. No significant
lethality was detected for Snx1;Snx2;H58 animals.
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phenotype, however, was more severe than the occasional ex-
encephaly seen in Snx2/;H58/ embryos because lethality
occurred several days later in the latter case. In both
Snx1/;Snx2/;H58/ and 40% of Snx1/;Snx2/ em-
bryos, the two waves of lethality at E8.5 and E13.5 are equally
represented.
Our phenotypic and genetic data indicate that SNX2 is more
critical for retromer function during development than SNX1,
although SNX1 does participate in retromer activity as evidenced
by the complete lethality associated with Snx1/;Snx2/;H58/
embryos versus the 90% lethality associated with Snx2/;H58/
embryos. This result is surprising because SNX2 has not been shown
to interact with any of the putative retromer components other than
itself and SNX1 (5, 14). The discrepancy between our genetic
evidence for SNX2 participation in retromer activity and the lack
of evidence for SNX2 interaction with retromer proteins may be
explained by species or temporal differences in SNX2 participation
in retromer activity. This discrepancy also may illustrate important
systemic differences between animal models and cultured cell lines.
Clearly, however, additional studies are needed to define the role
of SNX2 in mammalian retromer complexes.
Snx2 mRNA Is More Abundant Than Snx1 mRNA in the Extraembryonic
Yolk Sac During Development. Based on the severe lethality
and phenotypes we observed in Snx2/;H58/ and
Snx1/;Snx2/;H58/ embryos but not in Snx1/;H58/
or Snx1/;Snx2/;H58/ embryos, we hypothesized that
SNX2 is more abundant than SNX1 during development. To test
this hypothesis, we performed RT-PCR on embryonic and
extraembryonic tissues dissected from E8.5 wild-type embryos
(Fig. 1A) by using primers that are equally capable of amplifying
Snx1 or Snx2 cDNAs (Fig. 1B). Our results demonstrate that
Snx2 mRNA is more abundant than Snx1 mRNA in the extraem-
bryonic yolk sac at midgestation.
The abundance of Snx2 mRNA in the E8.5 yolk sac is
particularly interesting because H58 has also been shown to be
highly expressed in extraembryonic tissues from E6.5 throughout
midgestation by in situ hybridization (10). Lee et al. hypothesized
that normal expression of H58 may be required in extraem-
bryonic tissues for the proper development of embryonic ecto-
derm. This hypothesis arose from the paradoxical observation
that H58 depletion leads to growth retardation in the embry-
onic ectoderm at E7.5, although the gene is endogenously
expressed at much lower levels there than in the extraembryonic
visceral endoderm. The visceral endoderm and yolk sac as a
whole have both nutritive and inductive effects on developing
embryos (reviewed in refs. 15–17). Because Snx2 and H58 are
most highly expressed in the yolk sac at midgestation, we propose
that retromer complexes play a critical role in that tissue by
contributing to normal embryonic growth and development.
If retromer activity in the yolk sac is critical for normal
embryonic development as we hypothesize, our phenotypic data
may largely be explained by the availability of retromer compo-
nents in extraembryonic tissues at midgestation. Retromer com-
plexes can presumably contain either SNX1 or SNX2, as evi-
denced by the viability of Snx2/ and Snx1/ mice (9). When
SNX2, which is more abundant than SNX1 in the yolk sac, is
depleted and relatively low endogenous SNX1 levels are reduced
by half, enough functional retromer complexes are still able to be
assembled with the remaining SNX1 protein to support 60% of
Snx1/;Snx2/ embryonic survival beyond E13.5. However, if
H58 levels are also reduced by half in this context, the resulting
Snx1/;Snx2/;H58/ embryos all die by E13.5, thereby
demonstrating the importance of H58 levels for retromer
assembly at midgestation. Altogether, our molecular and genetic
data indicate the significance of SNX1 and H58 dosage levels
in the yolk sac for retromer activity, which is revealed only in the
context of SNX2 depletion.
CI-MPR Is Not Significantly Mistrafficked in H58, Snx1-, or Snx2-
Deficient Embryonic Fibroblasts, Yolk Sacs, or Visceral Endoderm. The
three classes of phenotypes revealed by our genetic crosses
indicate that three distinct checkpoints involving retromer func-
tion are critical for embryonic survival, suggesting that mam-
malian retromer complexes serve multiple roles during devel-
opment. Mammalian cell culture systems implicate retromer
complexes in trafficking of the CI-MPR from endosomes to the
trans-Golgi network, analogously to the retrograde trafficking of
Vps10p mediated by retromer complexes in yeast. Several recent
reports have described defective CI-MPR trafficking in small
interfering RNA-mediated SNX1- or H58-depleted HeLa cells
and in H58/ ES cells (2–4). These studies report severe
CI-MPR mislocalization with an increased rate of degradation,
presumably due to mistrafficking of CI-MPR to lysosomes when
retromer components are depleted in cells. We therefore rec-
ognized the importance of determining whether CI-MPR mis-
trafficking could be responsible for the phenotypes seen in our
embryonic models of retromer disruption.
To assess the status of CI-MPR localization and stability in our
retromer-deficient embryos, we generated multiple MEF cell
lines derived from wild-type, H58/, H58/, Snx1/,
Snx2/, and Snx1/;Snx2/ embryos. We found no evidence
of significant CI-MPR mislocalization as assessed by immuno-
fluorescence confocal microscopy with primary or permanent
mutant MEF cell lines (Fig. 2A; see also Fig. 5, which is published
as supporting information on the PNAS web site). In each case,
endogenous CI-MPR was predominantly localized in a perinu-
clear site, indicative of its function in the trans-Golgi network, as
has been observed in multiple cell lines of human and mouse
origin (2). We failed to observe cell-surface localization of
CI-MPR in our retromer-deficient MEFs as seen in H58/ ES
cells (4), nor did we observe significant cytoplasmic dispersal of
CI-MPR as observed in SNX1- or H58-small interfering RNA-
treated HeLa cells (2, 3). Furthermore, we did not find evidence
of increased colocalization between endogenous CI-MPR and
the early endosomal marker EEA1 in Snx1/;Snx2/ fibro-
blasts (Fig. 2A), as had been seen in H58-small interfering
RNA-treated HeLa cells (4). To determine whether loss of
retromer components affects CI-MPR stability in our MEF lines,
Fig. 1. Snx2 mRNA is more abundant than Snx1 mRNA in extraembryonic
yolk sacs at midgestation. (A) RT-PCR. Snx1, Snx2, and H58 were amplified by
RT-PCR from a litter of E8.5 wild-type embryos or their yolk sacs. (RT)
indicates mock RT reactions in which no reverse transcriptase was used. Equal
amounts of RT templates were used in each PCR, and identical amplifi-
cation conditions were used for all samples. This experiment was repeated
three times, and the quantitative averages of the data reveal that Snx2 mRNA
is expressed at 72% of Snx1 mRNA levels in the embryo, but Snx2 mRNA
levels are 225% of Snx1 mRNA levels in the yolk sac. (B) PCR amplification of
Snx1 and Snx2 cDNA for assessing primer pair amplification ability. Snx1 or
Snx2 cDNAs (0.15 ng) were PCR amplified with their gene-specific primers for
varying numbers of cycles to demonstrate the comparable ability of the
primers to amplify equal amounts of template.






we assessed CI-MPR degradation (Fig. 2 B and C). Immunoblot
analyses of lysates prepared from untreated cells or cells treated
for 17 h with cycloheximide show no indication of significant
receptor degradation. Together, our results strongly imply that
CI-MPR is not mislocalized nor mistrafficked to lysosomes and
degraded in our MEF cells derived from retromer-deficient
embryos.
The discrepancy between the lack of CI-MPR mislocalization
observed in our MEFs and the mislocalization reported by others
in SNX1- or H58-depleted HeLa cells (2–4) could be due to
species differences (mouse versus human cells), developmental
stage differences (embryonic versus adult cells), cell-type dif-
ferences (fibroblasts versus epithelium-like cells), or technical
differences (targeted mutations versus RNA interference treat-
ment). Species or developmental stage differences cannot, how-
ever, account for the dissimilarities seen in CI-MPR trafficking
between our H58/ MEFs and the H58/ ES cells described
by others in ref. 4. However, it is important to note that
fibroblasts are distinct from undifferentiated ES cells. Further-
more, our H58/ MEF cells were derived from embryos
carrying a targeted mutation of the H58 gene, whereas the
H58/ ES cells used in previous studies were derived from a
transgene insertion trap mouse line (11, 18), and it is likely that
other linked genes were affected. Thus, cell type differences or
technical differences in the derivation of H58/ MEFs versus
H58/ ES cells could account for the phenotypic differences
observed in CI-MPR trafficking between our studies.
Although retromer appears to be disabled in our MEF lines,
as evidenced by virtual depletion of the core cargo-binding
retromer component mVPS35 in our H58/ cell lines (Fig. 6,
which is published as supporting information on the PNAS web
site), alternative proteins such as TIP47, Rab9, or PACS-1
(19–21) could potentially compensate for retromer loss in our
MEFs, thereby masking any subtle CI-MPR mistrafficking phe-
notype we might otherwise observe. To exclude this possibility,
we assessed CI-MPR localization by using our mutant embryos
themselves, thereby circumventing issues of cell line derivation
and maintenance. Because of the particularly high levels of
endogenous H58 and Snx2 expression in the extraembryonic
yolk sac at the time during which mutant embryos begin to show
developmental delay (Fig. 1 A and ref. 10), we hypothesized that
the yolk sac would be an important site for assessing CI-MPR
mislocalization if it were occurring and contributing to the
lethality of our retromer-depleted embryos. We dissected
and immunostained whole yolk sacs from E8.5 H58/ and
H58/ littermates and yolk sacs from E8.5 Snx1/ and
Snx1/;Snx2/ littermates (Fig. 3 A–D). We found no evidence
of mislocalization of CI-MPR in mutant versus control yolk sacs.
In all cases, CI-MPR was found in a perinuclear location, similar
to what we observed in our MEF lines and to what others have
reported in other wild-type cell lines (2–4). We took an addi-
tional step to assess CI-MPR localization in a subset of extraem-
bryonic cells by dissecting and immunostaining visceral
endoderm surrounding the epiblast of E6.5 control and mutant
embryos (Fig. 3 E–H). We chose visceral endoderm for analysis
Fig. 2. CI-MPR sublocalization and stability is unaltered in wild-type versus
retromer-deficient MEF cell lines. (A) CI-MPREEA1 colocalization. Low pas-
sage, primary wild-type and Snx1/;Snx2/ MEF lines were fixed and stained
for endogenous CI-MPR (green) and EEA1 (red) and imaged by confocal
microscopy. Insets are magnifications of boxed areas, and arrowheads indi-
cate coincident labeling. (B) CI-MPR protein levels in Snx1/, Snx2/, and
Snx1/;Snx2/ MEFs. High passage, immortalized MEF lines were either left
untreated or were treated with 40 gml cycloheximide diluted in MEM for
17 h. Cell lysates were then immunoblotted with an anti-CI-MPR antibody,
followed by an anti-actin antibody to control for equal loading. (C) Quanti-
fication of CI-MPR stability in Snx1/, Snx2/, and Snx1/;Snx2/ MEFs.
Three separate experiments, such as those shown in B, were quantified, and
the data (mean  SEM) are expressed as a percentage of CI-MPR remaining
(dark gray bars) compared with untreated controls (light gray bars).
Fig. 3. CI-MPR localization is unaltered in control versus mutant extraem-
bryonic tissues. (A–D) CI-MPR localization in E8.5 extraembryonic yolk sacs.
H58/ versus H58/ and Snx1/ versus Snx1/;Snx2/ littermate em-
bryos were dissected and genotyped, whereas their yolk sacs were subjected
to whole mount immunofluorescence analysis with an anti-CI-MPR antibody
(green). Yolk sacs were mounted on glass slides with mounting media con-
taining DAPI (blue) before imaging. (Magnification: 40.) (E–H) CI-MPR
localization in E6.5 visceral endoderm cells. Visceral endoderm was separated
from the epiblasts of Snx1/ versus Snx1/;Snx2/ and H58/ versus
H58/ littermate embryos at E6.5. The embryos were genotyped, whereas
clumps of visceral endoderm cells were cytospun onto glass slides and sub-
jected to immunofluorescence analysis with an anti-CI-MPR antibody (green)
and mounting media containing DAPI (blue) before imaging. (Magnification:
100.)
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because H58 is highly expressed in this cell layer at E6.5 (10).
We detected no difference in immunostaining of CI-MPR in
visceral endoderm from Snx1/ versus Snx1/;Snx2/ litter-
mate embryos or from wild-type versus H58/ littermate
embryos and again found CI-MPR localized in a perinuclear site
similar to what we had observed in our MEF lines and in control
and mutant yolk sacs. Altogether, the normal localization of
CI-MPR in our mutant yolk sacs and visceral endoderm cells
corroborates the normal localization and stability of CI-MPR
observed in our MEF lines, thereby making the possibility very
unlikely that our MEF lines adapted to retromer depletion in
culture by using a compensatory mechanism for CI-MPR
trafficking.
Our data strongly suggest that mistrafficked CI-MPR is not
responsible for lethality of retromer-depleted embryos. Impor-
tantly, if increased turnover of the CI-MPR were responsible for
the embryonic phenotypes seen in our mouse models of retromer
depletion, we might predict that CI-MPR/ embryos would
share similar phenotypes with our genetic combinations of Snx1-,
Snx2-, and H58-deficiency. However, CI-MPR/ embryos do
not suffer any embryonic hemorrhage, exencephaly, or lethality
but rather exhibit overgrowth and postnatal lethality associated
with heart abnormalities (22–24). These studies provide strong
genetic evidence that CI-MPR mistrafficking and depletion are
not likely causes of the phenotypes observed in our retromer-
depleted embryos and indicate that the mechanism of retromer
function during development awaits further elucidation.
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